Advertisement
Screener

CytomX Therapeutics, Inc. (CTMX) Accumulated Other Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

CytomX Therapeutics, Inc. Accumulated Other Comprehensive Income

CytomX Therapeutics, Inc. (CTMX) had Accumulated Other Comprehensive Income of -$196.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06

  • 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$196.00K.
  • 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $102.00K.
  • 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $111.00K.
  • 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $104.00K.
Period endAccumulated Other Comprehensive Income (Loss), Net of Tax
2026-06-30-$196.00K
10-Q · filed 2026-08-06
2026-03-31$102.00K
10-Q · filed 2026-05-07
2025-12-31$111.00K
10-Q · filed 2026-08-06
2025-09-30$104.00K
10-Q · filed 2025-11-06
2025-06-30$33.00K
10-Q · filed 2025-08-07
2025-03-31-$1.00K
10-Q · filed 2025-05-12
2024-12-31$27.00K
10-K · filed 2026-03-16
2024-09-30$40.00K
10-Q · filed 2024-11-07
2024-06-30-$4.00K
10-Q · filed 2024-08-08
2024-03-31-$10.00K
10-Q · filed 2024-05-08
2023-12-31$95.00K
10-K · filed 2025-03-06
2023-09-30-$63.00K
10-Q · filed 2023-11-07
2023-06-30$35.00K
10-Q · filed 2023-08-08
2023-03-31$26.00K
10-Q · filed 2023-05-09
2022-12-31$10.00K
10-K · filed 2024-03-11
2022-09-30-$795.00K
10-Q · filed 2022-11-08
2022-06-30-$1.16M
10-Q · filed 2022-08-04
2022-03-31-$919.00K
10-Q · filed 2022-05-05
2021-12-31-$242.00K
10-K/A · filed 2023-03-27
2021-09-30$52.00K
10-Q · filed 2021-11-04
2021-06-30$15.00K
10-Q · filed 2021-08-05
2021-03-31-$43.00K
10-Q · filed 2021-05-06
2020-12-31-$47.00K
10-K/A · filed 2023-03-27
2020-09-30-$47.00K
10-Q · filed 2020-11-05
2020-06-30$16.00K
10-Q · filed 2020-08-06
2020-03-31$336.00K
10-Q · filed 2020-05-07
2019-12-31$57.00K
10-K · filed 2021-02-24
2019-09-30$110.00K
10-Q · filed 2019-11-07
2019-06-30$209.00K
10-Q · filed 2019-08-07
2019-03-31$73.00K
10-Q · filed 2019-05-09
2018-12-31-$93.00K
10-K · filed 2020-02-27
2018-09-30-$208.00K
10-Q · filed 2018-11-06
2018-06-30-$178.00K
10-Q · filed 2018-08-08
2018-03-31-$228.00K
10-Q · filed 2018-05-09
2017-12-31-$94.00K
10-K · filed 2019-02-27
2017-09-30-$61.00K
10-Q · filed 2017-11-07
2017-06-30-$110.00K
10-Q · filed 2017-08-07
2017-03-31-$100.00K
10-Q · filed 2017-05-05
2016-12-31-$27.00K
10-K · filed 2018-03-07
2016-09-30$6.00K
10-Q · filed 2016-11-03
2016-06-30$80.00K
10-Q · filed 2016-08-03
2016-03-31$30.00K
10-Q · filed 2016-05-06
2015-12-31-$76.00K
10-K · filed 2017-03-02
2015-09-30$8.00K
10-Q · filed 2015-11-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
CorMedix Inc. (CRMD)United States$0.605B3.25
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
Neurogene Inc. (NGNE)$0.625B-4.46
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
Indaptus Therapeutics, Inc. (INDP)United States$0.537B